Why the study?
With increasing interest in anti-stromal therapies to improve cancer outcomes, the LOX family has emerged as a potential clinical target, motivating an examination of its dysregulation, preclinical therapeutics, and biomarker potential.
Design
Review
Authors
Loading...
Should not yet guide anti-stromal decisions in solid tumors; leaves open prospective validation of LOX as target and marker.
The LOX family of enzymes represents a potential clinical target for anti-stromal therapies and a diagnostic/prognostic marker in solid tumors.
Setargew et al. (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: